Objective: The purpose of this study is to report updated clinical and aortic remodeling results from the Study for the Treatment of complicated Type B Aortic Dissection using Endoluminal repair (STABLE) trial, a prospective, multicenter study evaluating safety and effectiveness of a pathology-specific endovascular system (proximal stent graft and distal bare metal stent) for the treatment of complicated type B aortic dissection. Methods: All 86 enrolled patients (mean age, 59 years; 73.3% men) were treated within 90 days of symptom onset (55 with acute dissections and 31 with nonacute dissections). Inclusion criteria were branch vessel obstruction/compromise, impending rupture as evidenced by periaortic effusion/hematoma, resistant hypertension, persistent pain/symptoms, or aortic growth $5 mm within 3 months (or transaortic diameter $40 mm). Remodeling of the dissected aorta, including thrombosis of the false lumen and changes in the true lumen, false lumen, and transaortic diameter, were assessed in patients with available computed tomographic imaging through 2 years. Results: The 30-day mortality rate was 4.7% (4/86) in the overall patient group (5.5% in acute patients and 3.2% in nonacute patients). Freedom from all-cause mortality was 88.3% at 1 year and 84.7% at 2 years (no significant difference between acute and nonacute patients). From baseline to 2 years, the true lumen diameter increased significantly in the descending thoracic aorta and the more distal abdominal aorta, along with a decrease in the false lumen diameter in both aortic segments. A majority of patients had either a stable or shrinking transaortic diameter in the thoracic (80.3% at 1 year and 73.9% at 2 years) or abdominal aorta (79.1% at 1 year and 66.7% at 2 years). Transaortic growth (>5 mm) occurred predominantly in acute dissections. Consistently, a shorter time from symptom onset to treatment was found to predict transaortic growth in the abdominal aorta (P [ .03). Conclusions: Endovascular repair of complicated type B aortic dissection with the use of a composite construct demonstrates favorable early clinical outcomes and aortic remodeling. However, patients treated in the acute setting may be prone to aortic growth and may require close observation. Follow-up through 5 years is ongoing. (J Vasc Surg
The endovascular treatment of complicated type B aortic dissection (cTBAD) has evolved with time. Adaptation of the techniques applied for thoracic endovascular aneurysm repair has been a slow and deliberate process because of challenges presented by aortic dissections. With growing interest and demand, an increasing amount of clinical evidence has accumulated in the past decade, 1, 2 and endovascular repair of cTBAD has now become a widely accepted mode of treatment.
The Study for the Treatment of complicated Type B Aortic Dissection using Endoluminal repair (STABLE) study assesses the use of a dual-construct device, allowing for entry tear exclusion with an endograft while providing intimal support to the remaining aorta with the use of an uncovered bare metal dissection stent without obstruction of vital side branches. The 1-year data of the first 40 patients from the STABLE trial were previously published. 3 Whereas optimistic results of procedural success and 30day mortality rates were reported for this treatment in the literature, [4] [5] [6] [7] morphologic changes of the dissected aorta have not been fully characterized.
This study reports results through 2-year follow-up of all 86 patients enrolled in the STABLE study, focusing on aortic remodeling of the dissected aorta after endovascular treatment with the composite device design.
METHODS
STABLE study. STABLE is a prospective, nonrandomized, multicenter clinical study that evaluates the safety and effectiveness of a pathology-specific endovascular system (Zenith Dissection Endovascular System; Cook Medical, Bloomington, Ind). The study was conducted at institutions in the United States, Europe, and Australia and has completed its enrollment of a total of 86 patients (between December 2007 and February 2012). Study design, patient eligibility, and 12-month results from the first 40 enrolled patients were previously published. 3 In brief, patients with cTBAD were eligible if they met one or more of the following criteria: branch vessel obstruction/ compromise, impending rupture as evidenced by periaortic effusion/hematoma, resistant hypertension, persistent pain/symptoms, or aortic growth $5 mm within 3 months (or transaortic diameter $40 mm).
All patients enrolled in this study were treated within 90 days of symptom onset, including 55 patients treated within the acute phase (within 14 days of symptom onset) and 31 patients treated beyond the acute phase (or nonacute phase; >14 days of symptom onset). Because of the relatively small number of patients treated in the nonacute phase, results for these patients were not further divided into subacute and chronic groups.
The study's primary end point was 30-day mortality. All patients were to be followed up for 5 years after the initial endovascular treatment. The study was performed according to the Declaration of Helsinki II, with study approval obtained from the relevant ethics committee at each institution. All patients signed an informed consent to participate in the study.
Device description. The Zenith Dissection Endovascular System is a modular system specifically designed to treat aortic dissections. The system comprises the Zenith TX2 TAA Endovascular Graft with Pro-Form (proximal stent graft) and the Zenith Dissection Endovascular Stent (distal bare metal stent). During the implantation procedure, the TX2 stent graft component was first deployed to cover the primary entry tear. Subsequent deployment of the bare metal stent component was recommended if branch vessel obstruction or false lumen perfusion persisted and was performed at the discretion of each implanting physician. Detailed descriptions of the device, its implanting techniques, and recommendations for use of the bare stent were described previously. 3 Data analysis. Data were managed by a centralized data-coordinating center, MED Institute, Inc. Statistical analyses were performed with the use of SAS for Windows (release 9.1 or higher; SAS Institute Inc, Cary, NC) or other widely accepted statistical software. Continuous variables are reported as means and standard deviations unless otherwise noted, and categorical variables are reported as percentages. P values #.05 were considered significant.
Patients underwent clinical and imaging evaluation before discharge, at 1, 6, and 12 months, and yearly thereafter up to 5 years. Multiplanar contrast-enhanced computed tomographic angiography (CTA) was performed unless contraindicated before the procedure and during follow-up. The study protocol recommends the use of region of interest in the aortic arch to monitor enhancement before scan, and, for phase-delayed CT, a delay of 3 to 5 minutes from the end of the contrast scan. CT imaging was evaluated by each investigative site and centrally reviewed by an independent core laboratory blinded to the site assessments. Core lab review was performed with standardized protocols, definitions, and multiple quality assurance processes under the direction of a board-certified diagnostic radiologist with extensive experience. Unless indicated otherwise, data reported herein reflect the results from the core laboratory analysis. Aortic remodeling was assessed separately for the descending thoracic aorta and the abdominal aorta (divided by the celiac artery). Status of the false lumen was qualitatively assessed on CTA as patent (evidence of contrast without evidence of thrombus), partially thrombosed (evidence of both contrast and thrombus), or completely thrombosed (evidence of thrombus without evidence of contrast) in the descending thoracic aorta and abdominal aorta.
The maximum transaortic diameter, as well as the true lumen and false lumen diameter at the corresponding plane, was obtained for the descending thoracic aorta and abdominal aorta. The changes in the true lumen, false lumen, and transaortic diameters over time were analyzed with the use of a mixed model, which accounts for changes within each patient and allows for statistical comparisons between time points.
Aortic growth in the descending thoracic aorta or the abdominal aorta was defined as a >5 mm increase in the maximum transaortic diameter at a follow-up time point as compared with the measurement at postprocedure examination (or 30-day if postprocedure examination was not available). A generalized linear model was used to assess baseline characteristics that may be predictive of aortic growth.
RESULTS
This study reports available clinical and anatomical results through 2 years after the initial endovascular procedure, comprising data as of March 11, 2013 . Of 86 patients enrolled in this study, 13 patients died (as described below) and two patients withdrew from the study within 2 years. CT imaging was available in all 86 patients at preprocedure examination, in 79 patients at postprocedure examination, 67 patients at 12 months, and 48 patients at 24 months. Dissection characteristics and devices used. Of the total 86 patients (73.3% men; mean age, 59 years) enrolled in the STABLE study, 55 patients were treated in the acute phase of dissection (symptom onset to treatment: 4.2 6 3.7 days; range, 0-14 days) and 31 patients were treated in the nonacute phase (symptom onset to treatment: 40.5 6 22.5 days; range, 15-86 days). Patient demographics and medical history are summarized in Table I . Age, sex, and baseline comorbidities were similar between patients treated in acute and nonacute phases; hypertension was significantly more prevalent in patients treated in the nonacute phase.
As shown in Table II , the median number of clinical indications was three per patient (range, 1-5) in the overall patient group. The majority of patients (73.3%, 63/86) presented with impending aortic rupture (indicated by periaortic effusion or hematoma) and/or branch vessel malperfusion (based on clinical and/or imaging evaluation by the investigative sites). Significantly more nonacute dissections met the criterion of rapid transaortic growth ($5 mm within 3 months) or a large baseline transaortic diameter ($40 mm) (74.2% vs 34.5%; P < .001); most of these patients also met at least one clinical criterion. No significant difference was seen for other indications between acute and nonacute dissections. Anatomically, dissections treated in this study were extensive: of patients available for assessing the distal aspect of dissection, 98.6% (68/69) were classified as DeBakey 3b (with dissection extending below the diaphragm). Anatomical features including the locations of the primary tear and proximal or distal aspect of dissections were similar between patients treated in the acute and nonacute phases.
All patients received implantation of one or more TX2 stent grafts, and 80 patients (93.0%) received placement of at least one dissection stent. The combination of one TX2 component and one or more dissection stents was used most frequently in this study (Fig 1) .
Clinical outcomes: mortality, morbidity, and secondary interventions. The 30-day mortality rate was 4.7% (4/86) for the overall patient group, 5.5% (3/55) for patients with acute dissections, and 3.2% (1/31) for patients with nonacute dissections (P > .99). As summarized in Table III , the causes of deaths within 30 days were stroke in 2 patients, aortic rupture in the setting of chronic hypertension in 1 patient, and unknown in 1 patient. An additional nine deaths (four acute, five nonacute) occurred between 31 days and 24 months, four of which (one acute, three nonacute) were adjudicated as unrelated to the dissection repair by the clinical events committee. For the overall patient group, freedom from all-cause mortality was 88.3% at 1 year and 84.7% at 2 years ( Fig 2) , and freedom from dissection-related mortality (as adjudicated by the clinical events committee) was 90.6% at 1 year and 89.3% at 2 years. Between the acute and nonacute patients groups, there was no significant difference in freedom from all-cause mortality (87.1% vs 76.7% at 2 years; log-rank test, P ¼ .09) or from dissection-related mortality (88.9% vs 90.1% at 2 years; log-rank test, P ¼ .89).
The rates of notable clinical events are summarized in Table IV . No significant differences were observed for the event rates between the acute and nonacute patient groups. Five patients had aortic rupture within 2 years, with one occurring within 30 days, two between 31 days and 1 year, and two between 1 and 2 years. The occurrence of other adverse events, including stoke, paraplegia, renal failure, bowel ischemia, and retrograde dissection, was mostly limited to the first 12-month period.
There were no conversions to open surgical repair. Among the overall patient group, 21 patients underwent a total of 26 secondary interventions within 2 years, with the cumulative freedom from secondary interventions of 73.3%. The most common cause for the secondary interventions (a patient can be treated for multiple causes) was persistent entry-flow and/or sealing of re-entry tears (n ¼ 11), followed by malperfusion/ischemia (n ¼ 5), type A or retrograde dissection (n ¼ 5), device migration, separation, or kink (n ¼ 4), aneurysm growth or degeneration (n ¼ 3), and aortic rupture (n ¼ 2). Of note, there were no secondary interventions performed for malperfusion/ischemia beyond 30 days. Freedom from secondary interventions was similar between patients with acute dissections (72.7% at 2 years) and those with nonacute dissections (74.7% at 2 years; log-rank test, P ¼ .93).
Aortic remodeling: False lumen thrombosis. As shown in Table V , a completely thrombosed false lumen in the thoracic aorta (down to the celiac artery) increased significantly from 0% at preprocedure examination to 32.8% at 12 months and 43.5% at 24 months in the overall patient group (Cochrane Armitage Trend test, P < .001). All thoracic false lumens were either partially or completely thrombosed after the 30-day follow-up. In comparison, the rates of complete thrombosis in the abdominal false lumen were lower.
A patent false lumen was seen more frequently in acute dissections before treatment; however, there was no significant difference in the false lumen status (either the thoracic or abdominal aorta) between acute and nonacute dissections during follow-up.
Aortic remodeling: True and false lumens. Changes in the average diameters of the true lumen, false lumen, and total aortic lumen (ie, transaortic) were estimated from a mixed model, as shown in Table VI and illustrated in Fig 3. Overall, from baseline (preprocedure) to 2 years, a significant increase in the average true lumen size, along with a significant decrease in the false lumen size, was observed in both the thoracic aorta and the abdominal aorta. Such remodeling was seen in both acute and nonacute dissections, occurring early after the endovascular treatment, with subsequent changes occurring mostly within 12 months.
True lumen. The endovascular treatment led to early, significant expansion of the true lumen in both the descending thoracic aorta and the abdominal aorta, as seen at the postprocedure time point. The true lumen continued to expand significantly in the thoracic aorta during follow-up, whereas its size remained relatively stable in the abdominal aorta. Trends in true lumen expansion were similar between acute and nonacute dissections. 
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False lumen. At postprocedure examination, the false lumen decreased in size significantly in both the thoracic aorta and abdominal aorta. In the thoracic aorta, the false lumen continued to decrease in size during follow-up, with a larger shrinkage observed in nonacute dissections. In the abdominal aorta, the false lumen remained stable in nonacute dissections; however, a small yet significant increase in the false lumen size was seen in acute dissections after postprocedure examination.
Aortic remodeling: Transaortic diameter. The average transaortic diameters generally increased slightly after surgery. During the subsequent follow-up, the transaortic diameter of the thoracic aorta remained relatively stable in the acute dissections, while showing a significant decrease in nonacute dissections. In the abdominal aorta, the transaortic diameter increased significantly in acute dissections, mostly attributed to an increased false lumen size, whereas the transaortic diameter stayed relatively stable in nonacute dissections.
Changes in the maximum transaortic diameter were further categorized into growth (increase of >5 mm), shrinkage (decrease of >5 mm), or no change (increase or decrease within 5 mm), as shown in Table VII. In the overall patient group, a majority had either a stable or a shrinking aorta in the thoracic segment (80.3% at 1 year and 73.9% at 2 years) or the abdominal segment (79.1% at 1 year and 66.7% at 2 years). A >5 mm growth in the transaortic diameter was observed more frequently in acute dissections than in nonacute dissections, with a significant difference seen at 12 months for the thoracic aorta (P ¼ .012) and at 24 months for the abdominal aorta (P ¼ .008).
A generalized linear model was used to assess baseline factors that may be predictive of transaortic growth. An outcome of growth in this model was defined as a >5 mm increase in the maximum transaortic diameter within 24 months as compared with postprocedure examination (or 30-day if postprocedure examination was not available). The factors examined include age, Society for Vascular Surgery-International Society for Cardiovascular Surgery (SVS-ISCVS) risk score of hypertension, indications for treatment (categorized into "impending rupture or malperfusion" and "other criteria"), duration from symptom onset to treatment, baseline transaortic diameter, and baseline presence of secondary tears. Consistent with the above observation of more frequent growth in acute dissections, shorter duration from symptom onset to treatment was the only significant predictor of transaortic growth in the abdominal aorta (P ¼ .03). No significant predictors were identified for transaortic growth in the thoracic aorta.
DISCUSSION
The indications for treatment of cTBAD in this report represent the most common circumstances requiring intervention beyond medical management. The threatening findings of periaortic hematoma and effusion along with malperfusion represented 73% of our patient population. The mean number of 3 indications per patient also suggests that the study cohort was representative of complicated circumstances. The need to be aggressive with patients presenting with recurrent and persistent pain and hypertension is well documented and worth reemphasizing. 3, 8 Mortality and morbidity. The 30-day mortality of 4.7% compares favorably with the literature on endovascular repair of cTBAD. 2, [9] [10] [11] Beyond the initial 30-day period comes the important process of follow-up and close observation. In this study, several patients had retrograde type A dissection (3/7) and aortic rupture (4/5) outside of the 30-day window. The etiology of retrograde dissection cannot be solely ascribed to technique because three of seven patients were beyond 30 days with no CT evidence of ascending aorta involvement on prior follow-up CT scans. An important contributing factor was placement of the stent graft in a dissected sealing zone segment of the aorta (4/7 patients). Still, manipulation of the dissected thoracic aorta will always have a risk for retrograde propagation in the postprocedural phase and beyond. 12, 13 The importance of long-term follow-up after endovascular repair of dissected thoracic aorta is also echoed in other reports. [14] [15] [16] The incidence of stroke was observed exclusively among the acute patients, with the majority (6/7) presenting within 30 days. These patients uniformly had anteriorposterior, bi-hemispheric embolic stroke. The distribution of these infarcts suggests a possible technical component with catheter and device manipulation, and, more importantly, reemphasizes the fragility of the aorta in the acute phase and the need to be meticulous with planning, device preparation, and endovascular technique.
False lumen thrombosis. The relevance of false lumen thrombosis with long-term outcome has been demonstrated in earlier studies. 17, 18 In the present study, a significant increase in complete thrombosis was seen in the thoracic false lumen over timedabout half of the patients achieved complete thrombosis at 2 years. Still, many patients had incomplete false lumen thrombosis during follow-up, and persistent flow into the abdominal false lumen was even more prevalent. Such flow was primarily through intercostal collateral sources or through re-entry tears, the treatment of which was not mandatory and was performed at the discretion of implanting physicians. 
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Of note, the relatively lower rate of complete false lumen thrombosis in the thoracic aorta, as observed in the current study, may be related to a rather stringent definition of false lumen involvement (entire segment from the left subclavian artery to celiac) and probably is influenced by the strategy of minimal proximal coverage followed by distal bare support. Although minimally discussed, other strategies may favor more extensive thoracic coverage, which is believed to give a greater rate of false lumen thrombosis. 19 Greater coverage of the thoracic aorta may result in greater false lumen thrombosis but also increases the risk of spinal ischemia, which was notably low in this study.
Size of dissected aorta. The importance of aortic remodeling after endovascular repair of dissection has been well described. 17, 20 In the present study, despite the true lumen augmentation and false lumen regression observed overall after treatment, the fate of the dissected abdominal aorta remains unclear. The nonacute patients had a significant decrease in thoracic aortic diameter and a stable abdominal aortic diameter. However, in acutely treated patients, the dissected abdominal aorta appears to be more prone to aortic expansion over time.
Our findings suggest that in acute dissections, growth in the abdominal aorta after treatment was mainly attributed to an expansion in the false lumen, whereas the true lumen remained unchanged in size. As mentioned earlier, persistent flow into the abdominal false lumen was present in a majority of patients during follow-up. Continued pressurization in the false lumen may lead to its expansion as the aortic wall continues to weaken during follow-up.
However, persistent false lumen flow does not appear to be the sole factor leading to aortic growth. We found that a large portion of patients with persistent false lumen flow in the thoracic or abdominal aorta did not have growth in the respective aortic segments. Also, we found that the status of false lumen after repair was similar between acute and nonacute dissections, which had very distinctive outcomes in terms of aortic growth. Therefore, false lumen flow does not appear to be the main factor causing the different growth patterns between these groups. The pathophysiological features of the dissected aorta at the time of treatment (and how the aorta responds to changed hemodynamics) may be an important factor.
Aortic growth after endovascular treatment of type B aortic dissection has been reported by others. A report by Sobocinski et al 21 Table IV. cTBAD after proximal endografting alone, which agrees with our findings. This report observed a transaortic growth >5 mm in 25% and 33% of the patients at 12 months for thoracic aorta and abdominal aorta, respectively. Another report by Sayer et al 22 reviewed both acute and chronic dissections treated with endovascular repair, in which their acute cohort showed a 20% expansion rate of the thoracic aorta with endografting alone. Although this report did include nine patients with either intra-mural hematoma or penetrating ulcer, which were not included in this study, a thoracic false lumen thrombosis rate of just over 50% at 24 months does parallel our data at 48.4%. Expansion of the uncovered aorta distal to the stent graft was also observed in 16% of acutely treated patients in a study by Resch et al 23 Moreover, in a recent report from the International Registry of Acute Aortic Dissection registry, aortic growth or new aneurysm occurred in up to 73% of patients at 5 years after endovascular repair of acute TBAD, highlighting the risk of disease progression in this patient population. 24 On the basis of these findings, long-term aortic dilatation, particularly in the abdominal aorta, is a phenomenon that must be surveyed methodically on follow-up imaging.
As we understand the natural history of cTBAD better, it is unlikely that endovascular therapy actually "treats" or "resolves" the dissection. The idea of "management" may be more appropriate because it denotes a long-term commitment to patients in whom the dissected aorta is prone to complications. Although the majority of patients in our study presented with a grave situation and resulted with a favorable clinical outcome, progression of disease in the long term must be monitored closely. The management process then ensues with a focus on false lumen status, with secondary interventions performed as needed, to minimize the risk of aortic rupture from aneurysmal growth/degeneration.
Bare metal dissection stent. Previous reports indicate that remodeling (true lumen expansion and false lumen shrinking) of the dissected aorta is often limited to the thoracic aorta with stent graft coverage. 22, 25, 26 With the use of the distal bare metal stent, however, significant true lumen expansion was achieved not only in the thoracic aorta but also in the distal abdominal aorta in the current study. This finding is also consistent with the single-center volumetric analysis on the same system. 20 Besides true lumen expansion, placement of the bare metal stent may help stabilize the intimal flap while allowing for interrogation of the target vessels through the interstices of the stent to reestablish flow.
The limitations of this study include 24-month morphometric analysis in a subset of patients with adequate imaging for core lab analysis as well as the lack of longer-term followup. The limited sample size in the acute and nonacute groups Table VII . Changes in the maximum transaortic diameter in the descending thoracic aorta and abdominal aorta, categorized by growth (>5 mm increase), shrinkage (>5 mm decrease), or no change (increase or decrease within 5 mm) may be underpowered to detect differences between these two groups. Given the single-arm design of the STABLE study, the current analysis was performed mainly to characterize aortic remodeling after treatment with the composite system rather to than delineate the role of the bare stents. In addition, because the study did not collect information on the length of aorta encompassed by covered stent grafts and bare stents, we were not able to examine how the extent of coverage affects aortic remodeling.
CONCLUSIONS
The use of proximal endografting combined with a distal bare metal stent produces favorable mortality rates and among the lowest reported paraplegia rates. However, our data suggest that patients treated in the acute setting are more prone to abdominal aortic dilatation. This potential risk should be recognized when patients must undergo immediate dissection repair for life-threatening symptoms such as acute malperfusion or impending/frank aortic rupture. Data accumulation is currently ongoing to obtain follow-up results through 5 years. Longer-term follow-up results, particularly the need for secondary interventions, are required to understand the effectiveness of endovascular repair for the treatment of cTBAD.
The authors thank Omke Teebken, MD, and Anthony Lee, MD, for their contribution to this work and Priya Bharadwaj, PhD, from MED Institute, Inc, a Cook Group Company, for her contribution in data collection and analysis. Dr Joseph V. Lombardi (Camden, NJ). Based on the data that we're seeing now, we're observing a lot of increased false lumen flow. I think the natural tendency of everyone is to increase your coverage zone down to the celiac artery for your proximal piece. However, the STABLE trial has demonstrated a very low 1.2% paraplegia rate and I think one of the advantages of using one short-body TX2 device followed by a long bare stent. Theoretically, the observed enhanced false lumen flow has minimized paraplegia and combined with low mortality rates, it seems to do the job while minimizing complications.
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As far as the bare stent, from my standpoint, I think it comes down to what your patient looks like anatomically. If they have extensive malperfusion distally, then I would extend that bare stent all the way down to the bifurcation; if it looked like there was a very focal area, then I would minimize its coverage.
Dr Jon Matsumura (Madison, Wisc). What is the definition of thoracic versus abdominal aorta? Is it at the diaphragm? Is it at the celiac? Does abdominal aorta growth mean that these patients will require a type IV thoraco-abdominal repair?
If the abdominal aorta is defined at the celiac, have you modified your treatment in that when you need to go back and treat patients with abdominal aortic growth either with another renal stent or maybe an open repair, how do you feel about having the bare aortic stent there? Do you feel like there is a different approach you should do at that initial operation that might make that second repair simpler? Dr Lombardi. We define the thoracic aorta from the celiac and above, abdominal is below, based on our core lab data, and that's how they measured our false lumen patency. Now, if you have a bare metal stent crossing through the perivisceral aorta, which 80 of our patients had, and then you notice growth, having that stent there approximates the intima with your target visceral artery. So if you're looking to bring back the target vessel that has a reentry tear back in continuity with the true lumen, it's much easier with the bare stent present. Working through that stent is pretty facile, just like a fenestrated stent graft at the end of it all. There are smaller little intimal tears that are from the intercostals that may persist; however, when you tackle the large entry tears, you usually minimize flow to the degree where you can stabilize growth.
Dr Juan Parodi (San Isidro, Argentina). I have a question. It seems that we don't have solutions yet for the abdominal aorta in the long term, and we see these more and more as we follow our patients' dilatation of the abdominal aorta in type IIIb. It seems that with your system you can achieve positive remodeling of the true lumen. The problem is the false lumen. We are conducting studies in which we are seeing that the diastolic pressure in the false lumen is higher than in the true lumen and through numerical models, and, mechanical models and some anecdotal measurements, we are seeing that we need another treatment to complete this, either do percutaneous septotomy or perhaps using branches and complete the occlusion of the entry sites of the distal aorta. What do you think about it?
Dr Lombardi. I believe that's largely true. Persistent flow in the false lumen and the abdominal aorta is the Achilles' heel and responsible for growth. I think from a basic standpoint covering the reentry tears and minimizing flow into that segment has substantial value in the setting of growth. It's more or less anecdotal at this point because we don't have a host of patients to really to compare with those who did not achieve those procedures. Secondary procedures, particularly if patients are treated in the acute phase, are going to be common to this pathology and management.
Dr Manju Kalra (Rochester, Minn). I just have two quick questions for you. Do you have a theoretical explanation for why you had continued growth in the group of patients that were treated in the acute phase within the first 2 weeks compared to those treated later? And do you think, when you have a larger group of patients, you're going to be able to make a recommendation as to preferred timing of treatment based on this data? Dr Lombardi. That's the question, isn't it? From the standpoint of patients with malperfusion and rupture, you have no choice. So you're treating them when they present. Most of the patients who present in the acute phase have those two problems. So from a standpoint of watchful waiting, and potentially waiting after 14 days to treat them, that might provide you some value in patients in whom you think you can wait on, but again that clinical scenario rarely will come up.
As to why it happens, I don't know. I think that in the acute phase there is inflammation and a very suggestible intimal membrane which maybe you set off a course or a series of events where the aorta just is unable to stabilize. But I don't have a very good explanation for that at this time. We clearly need to follow those patients closely, however.
Dr B. Timothy Baxter (Omaha, Neb). It looked like your rupture rate was higher in the growth group versus the no-growth group. Where are the ruptures occurring in these patients, and is there something that you could be looking for to try to prevent the rupture? Dr Lombardi. We were unable to get an autopsy on the patients who ruptured, so we really don't know exactly where that occurred anatomically. They presented with back pain and most of them expired before we could fully evaluate the location of their ruptures. But we suspect they were all in the thoracic aorta.
However, you mentioned the increased rate of rupture in patients in the thoracic aorta with growth; although not significant, we had an equally converse situation in the abdominal aorta where the patients who had no growth had a higher mortality and rupture. So that was a little counterintuitive, not something I would have predicted; however, that's how it worked out. So, based on the data thus far, we can't predict rupture based on morphology and growth.
